Monitor Q4 2026 results for revenue acceleration and whether gross margin improvement sustains. The narrowed guidance range suggests management sees limited upside to the full-year outlook. Watch for updates on the patent litigation post-verdict motions.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $5.40entry
- T+1 · 11d ago +7.96%α +7.65% · $5.83
- T+5 · 5d ago +2.22%α −1.07% · $5.52
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Cytek Biosciences reported Q3 2026 revenue of $53.2M, slightly above the $52.9M consensus, but GAAP EPS of -$0.05 beat the -$0.07 estimate. Revenue grew only 2% YoY, and adjusted EBITDA fell sharply to $0.7M from $2.5M a year ago. The company narrowed full-year revenue guidance to $208M-$211M, maintaining the midpoint, while gross margin improved 590 bps to 59%.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $53.2M, +2% YoY vs $52.3M
- GAAP EPS -$0.05 vs consensus -$0.07 (beat)
- GAAP gross margin 59%, up 590 bps YoY from 53%
- Adjusted EBITDA $0.7M vs $2.5M in Q3 2025
- Full-year 2026 revenue guidance narrowed to $208M-$211M, midpoint maintained
- Recurring revenue (trailing 12-month) 36% of total, up from 33%
- Installed base grew by 140 units to 4,073
- U.S. revenue grew 12% YoY; high-end instrument revenue up 11%
- Net loss $6.1M vs $5.5M in Q3 2025
- Cash & securities $256.3M, down $5.7M from Q2 2026
Financial Impact
Revenue slightly above consensus; EPS beat by $0.02; adjusted EBITDA declined $1.8M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | $37.2M | -2.5% |
| Service | $16.1M | +13.3% |
Risk Factors
- Revenue growth decelerated to 2% YoY, well below prior quarters
- Adjusted EBITDA declined sharply despite gross margin expansion
- Net loss widened YoY; operating cash flow not disclosed
- Litigation expenses weighing on G&A; post-verdict motions and potential appeal create uncertainty
- Full-year guidance midpoint implies Q4 revenue of ~$55M-$58M, requiring acceleration from Q3's $53.2M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395793 |
Track record
14 reports on CTKB
1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +1.49% at T+1 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 20261d ago ITC Section 337 Neutral 3/10 Entry $5.78 Now $5.63 −2.60% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $5.84 to $5.63 Now $5.63 −3.60% ▼ −3.60% −1.68% vs SPY
- Nov 10, 20266d ago Institutional Cluster Bullish 4/10 Entry $5.79 to $5.76 Now $5.63 −2.76% ▼ −0.52% −1.84% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $5.40 to $5.83 Now $5.63 +4.26% ▲ +7.96% +7.65% vs SPY
- Nov 3, 202613d ago SC 13G/A Neutral 2/10 Entry $5.88 to $5.40 Now $5.63 −4.25% ▼ −8.16% −3.75% vs SPY
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $5.43 to $5.59 Now $5.63 +3.68% ▲ +2.95% +3.47% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $5.71 to $5.68 Now $5.63 −1.40% ▼ −0.53% +0.19% vs SPY
- Aug 24, 202612w ago 8-K Bearish 7/10 Entry $4.44 to $4.58 Now $5.63 −26.80% ▼ −3.15% −2.83% vs SPY
- Jun 25, 202620w ago 8-K Neutral 2/10 Entry $4.48 to $4.34 Now $5.63 +25.67% ▼ −3.13% −4.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers